var data={"title":"Craniopharyngioma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Craniopharyngioma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributors\" class=\"contributor contributor_credentials\">Griffith R Harsh, IV, MD, MBA</a></dd><dd><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributors\" class=\"contributor contributor_credentials\">Lawrence D Recht, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributors\" class=\"contributor contributor_credentials\">Karen J Marcus, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributors\" class=\"contributor contributor_credentials\">Jay S Loeffler, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributors\" class=\"contributor contributor_credentials\">Patrick Y Wen, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributors\" class=\"contributor contributor_credentials\">Amar Gajjar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/craniopharyngioma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 18, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Craniopharyngiomas are rare solid or mixed solid-cystic tumors that arise from remnants of Rathke's pouch along a line from the nasopharynx to the diencephalon [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/1\" class=\"abstract_t\">1</a>]. Historically, these have also been referred to as Rathke pouch tumors or hypophyseal duct tumors.</p><p>The epidemiology, pathology, diagnosis, management, and outcomes after treatment of craniopharyngiomas are reviewed here.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the United States, there are an estimated 350 new cases of craniopharyngioma diagnosed each year, constituting approximately 1 to 3 percent of all brain tumors [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Craniopharyngiomas comprise approximately 5 to 10 percent of brain tumors in children [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/3,4\" class=\"abstract_t\">3,4</a>]. In other parts of the world, craniopharyngiomas appear to be more common, with higher incidence rates reported in Japan and some parts of Africa [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Craniopharyngiomas are approximately equally common in males and females.</p><p>There is a bimodal age distribution, with one peak in children between 5 and 14 years, and a second peak in adults between 50 and 75 years of age [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/2\" class=\"abstract_t\">2</a>]. Adamantinomatous craniopharyngiomas are more common in the pediatric age group, while papillary craniopharyngiomas are seen predominantly in adults [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"#H3\" class=\"local\">'Pathology and molecular genetics'</a> below.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOLOGY AND MOLECULAR GENETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Craniopharyngiomas are epithelial tumors that usually arise in the pituitary stalk in the suprasellar region, adjacent to the optic chiasm. A small percentage arise within the sella [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/8,9\" class=\"abstract_t\">8,9</a>], and a few tumors have been described within the optic system or the third ventricle [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/10-12\" class=\"abstract_t\">10-12</a>].</p><p>Although benign histologically, these tumors frequently shorten life and should be considered low-grade malignancies. Most craniopharyngiomas contain both solid and cystic components. The cysts are filled with turbid fluid that contains cholesterol crystals.</p><p>In the World Health Organization classification of central nervous system tumors, craniopharyngiomas are divided into two categories, adamantinomatous craniopharyngiomas and papillary craniopharyngiomas [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/7\" class=\"abstract_t\">7</a>]. In addition to being histologically disparate, these tumor types have distinct molecular genetics as well.</p><p>Adamantinomatous craniopharyngiomas appear to be driven by activation of the Wnt signaling pathway, and the vast majority harbor activating mutations in <em>CTNNB1,</em> the gene encoding &beta;-catenin [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/13-15\" class=\"abstract_t\">13-15</a>]. By contrast, papillary craniopharyngiomas commonly harbor mutations in the <em>BRAF</em> oncogene [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/15\" class=\"abstract_t\">15</a>]. In the largest study to date, mutations in <em>CTNNB1</em> were identified in 96 percent of 53 adamantinomatous tumors and <em>BRAF</em> V600E mutations were identified in 95 percent of 39 papillary tumors [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/15\" class=\"abstract_t\">15</a>]. &#160; </p><p>The prognostic importance of tumor type is uncertain; older series have found that these two histologic subtypes behave similarly with respect to resectability, sensitivity to radiation, and overall survival [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/16,17\" class=\"abstract_t\">16,17</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Craniopharyngiomas are slow growing, and symptoms often are present for a year or more before the diagnosis is established [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/18,19\" class=\"abstract_t\">18,19</a>]. A wide range of symptoms may be present, depending upon the precise location of the tumor and its relationship to adjacent normal structures.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Visual symptoms &ndash; Visual symptoms are frequent, and deficits on formal ophthalmologic assessment are present in the majority of patients. These can be a direct result of pressure on the optic chiasm; the specific deficit depends upon the growth pattern of the tumor.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endocrine abnormalities &ndash; Direct damage to or compression of normal structures can lead to a range of endocrine abnormalities. Frequently observed complications include deficiencies of growth hormone, gonadotropin, thyroid stimulating hormone, and adrenocorticotropic hormone in an estimated 75, 40, 25, and 25 percent of cases, respectively [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/4\" class=\"abstract_t\">4</a>]. Diabetes insipidus is frequent when the pituitary stalk is involved.</p><p/><p class=\"bulletIndent1\">Growth failure, which can be caused by either hypothyroidism or growth hormone deficiency, is the most common presentation in children. Sexual dysfunction is the most common endocrine manifestation in adults; almost 90 percent of men complain of erectile dysfunction, while most women have amenorrhea. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Headache &ndash; Moderate to severe daily headaches are present in approximately 50 percent of patients at the time of diagnosis [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/20\" class=\"abstract_t\">20</a>]. These may result from traction on pain-sensitive structures by the tumor itself, obstructive hydrocephalus from tumor compression of the third ventricle, or meningeal irritation by escaped cyst contents.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other symptoms &ndash; Craniopharyngiomas can also cause other generalized symptoms, such as depression, independent of any hormone deficiency. The presumed cause is extension of tumor into the frontal lobes, striatal and thalamic areas, or limbic system. Nausea, vomiting, and lethargy can accompany pressure-related headaches.</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>At the time of diagnosis, craniopharyngiomas vary in size from small, solid, well-circumscribed masses to huge multilocular cysts that invade the sella turcica and displace neighboring cerebral structures. </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Neuroimaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Preoperatively, the diagnosis of craniopharyngioma is usually suggested by the presence of a mass on magnetic resonance imaging (MRI) <span class=\"nowrap\">and/or</span> computed tomography (CT).</p><p>Calcification in the suprasellar region is seen in 60 to 80 percent of patients with craniopharyngioma and one or more cysts are present in approximately 75 percent. Thus, a cystic calcified parasellar lesion is very likely to be a craniopharyngioma (<a href=\"image.htm?imageKey=ENDO%2F70146\" class=\"graphic graphic_diagnosticimage graphicRef70146 \">image 1</a> and <a href=\"image.htm?imageKey=ONC%2F72783%7EONC%2F80882\" class=\"graphic graphic_diagnosticimage graphicRef72783 graphicRef80882 \">image 2A-B</a>). Calcifications can also sometimes be seen on CT or plain skull radiographs. In some patients, no calcification is seen on radiologic testing. In these patients, the diagnosis can only be established histologically.</p><p>Craniopharyngiomas must be distinguished from other tumors in the parasellar area, including pituitary macroadenoma, meningioma, optic glioma, germinoma, teratoma, lymphoma, metastasis, from non-neoplastic cysts (Rathke's, pars intermedia, and arachnoid), and from infiltrative disorders such as sarcoidosis and systemic histiocytosis [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=causes-presentation-and-evaluation-of-sellar-masses#H14\" class=\"medical medical_review\">&quot;Causes, presentation, and evaluation of sellar masses&quot;, section on 'Cysts'</a> and <a href=\"topic.htm?path=causes-presentation-and-evaluation-of-sellar-masses\" class=\"medical medical_review\">&quot;Causes, presentation, and evaluation of sellar masses&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Pretreatment evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since most patients with craniopharyngioma have at least partial hypopituitarism, endocrine testing, particularly of adrenal and thyroid function, is indicated before surgery. (See <a href=\"topic.htm?path=diagnostic-testing-for-hypopituitarism\" class=\"medical medical_review\">&quot;Diagnostic testing for hypopituitarism&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-adrenal-insufficiency-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of adrenal insufficiency in adults&quot;</a>.)</p><p>A detailed neuroophthalmologic examination including visual field testing helps to determine whether there is compression of the optic pathways and establishes a presurgical baseline. (See <a href=\"topic.htm?path=causes-presentation-and-evaluation-of-sellar-masses#H19\" class=\"medical medical_review\">&quot;Causes, presentation, and evaluation of sellar masses&quot;, section on 'Visual defects'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Historically, the optimal treatment of craniopharyngiomas has been controversial and included two basic approaches: aggressive surgery with an attempt to achieve complete resection at diagnosis versus a more conservative surgical approach that used radiation therapy (RT) to treat residual disease [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Major advances in neurosurgical techniques have significantly decreased the morbidity and mortality associated with resection, making aggressive resection feasible in more cases. At the same time, improvements in RT techniques have permitted more accurate delivery of radiation to the tumor target, while minimizing radiation damage to normal structures. (See <a href=\"#H9\" class=\"local\">'Surgery'</a> below and <a href=\"#H10\" class=\"local\">'Radiation therapy'</a> below.)</p><p>An experienced multidisciplinary team (neurosurgery, RT, neuro-oncology, endocrinology, ophthalmology) is essential for the optimal treatment of both pediatric and adult patients with craniopharyngiomas [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/4,19,22\" class=\"abstract_t\">4,19,22</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgery is indicated in almost all cases. The goal of surgery is to establish the diagnosis, alleviate mass-related symptoms, and remove as much tumor as is safely possible. Some neurosurgeons advocate a strategy of reduction of neural compression by cyst drainage and limited resection of solid tumor in anticipation of irradiation of residual tumor. Many others argue that the initial operation offers the best chance for surgical cure and attempt complete total tumor removal when it can be accomplished with a low risk of neurologic injury. &#160;</p><p>Preoperative management should include treatment of disease-related complications that may be present and can increase the risk associated with surgery:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endocrine function should be assessed and significant abnormalities corrected prior to surgery if possible. (See <a href=\"topic.htm?path=diagnostic-testing-for-hypopituitarism\" class=\"medical medical_review\">&quot;Diagnostic testing for hypopituitarism&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypopituitarism\" class=\"medical medical_review\">&quot;Treatment of hypopituitarism&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peritumoral edema and increased intracranial pressure should be controlled. (See <a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults\" class=\"medical medical_review\">&quot;Evaluation and management of elevated intracranial pressure in adults&quot;</a> and <a href=\"topic.htm?path=management-of-vasogenic-edema-in-patients-with-primary-and-metastatic-brain-tumors\" class=\"medical medical_review\">&quot;Management of vasogenic edema in patients with primary and metastatic brain tumors&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hydrocephalus may require either a temporary or permanent shunt.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with a large cystic component to their tumor may require specific treatment (aspiration) prior to surgery. (See <a href=\"#H13\" class=\"local\">'Cyst management'</a> below.)</p><p/><p>The surgical approach depends upon the location of the tumor. Intrasellar tumors may be removed transsphenoidally. An extended transsphenoidal approach, now commonly performed using the endoscope, can remove intrasellar tumors and some with suprasellar extension [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/23\" class=\"abstract_t\">23</a>]. Many craniopharyngiomas are currently approached by a pterional craniotomy. Far superior extension of a cyst into the third ventricle may require opening of the lamina terminalis or an approach from above, through the foramen of Monro.</p><p>While several small retrospective studies suggest that rates of obesity and diabetes insipidus may be lower in patients treated with more conservative surgical approaches [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/24,25\" class=\"abstract_t\">24,25</a>], prospective studies with long-term follow-up are needed to better compare the full range of outcomes with various contemporary surgical and RT techniques. </p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Radiation therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>RT can be used to treat patients with residual disease who have undergone a partial surgical resection or to treat disease that has recurred following what was initially thought to be a gross total resection [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/26\" class=\"abstract_t\">26</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">RT techniques</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contemporary RT techniques permit greater treatment precision and conformity. These approaches decrease but do not eliminate long-term toxicity by limiting the exposure of surrounding normal tissues to ionizing radiation [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/27\" class=\"abstract_t\">27</a>]. Techniques that have been used in the treatment of craniopharyngioma to provide highly conformal, image-guided radiation include stereotactic radiotherapy [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/26,28-30\" class=\"abstract_t\">26,28-30</a>], intensity-modulated radiation therapy (IMRT), and proton beam therapy [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/31-33\" class=\"abstract_t\">31-33</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stereotactic techniques &ndash; Stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) utilize head fixation that permits establishment of a patient-specific coordinate system for imaging, treatment planning, and delivery. Imaging of applied fiducial markers or facial contours permits localization of the patient's head and tumor within this coordinate system, allowing precise delineation of the target treatment volume and accurate description of the planned radiation field. (See <a href=\"topic.htm?path=stereotactic-cranial-radiosurgery\" class=\"medical medical_review\">&quot;Stereotactic cranial radiosurgery&quot;</a>.)</p><p/><p class=\"bulletIndent1\">SRT uses a fully fractionated treatment schedule, usually approximately 30 fractions, to minimize damage to normal structures, while allowing coverage of a relatively large target volume. SRS uses one to five fractions; it is an acceptable alternative to more extensively fractionated radiotherapy for small tumors or small focal postoperative residuals. For both SRT and SRS, care must be taken to keep the dose within the tolerance of the optic nerves, chiasm, and tracts.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intensity-modulated RT &ndash; IMRT is a three-dimensional (3D) technique that uses complex treatment planning and dynamic delivery of irradiation to optimize the delivery of radiation to irregularly shaped volumes. This technique can be added to 3D-conformal or SRT (whether delivered by photons or protons) to shape the beam to the irregular contours of the tumor. (See <a href=\"topic.htm?path=radiation-therapy-techniques-in-cancer-treatment#H1070824621\" class=\"medical medical_review\">&quot;Radiation therapy techniques in cancer treatment&quot;, section on 'Intensity-modulated radiation therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Proton beam RT &ndash; Heavy particle irradiation techniques such as proton beam use charged particles rather than photons to deliver high doses of radiation to the target volume while limiting the &quot;scatter&quot; dose received by surrounding tissues. There is minimal radiation exposure beyond the Bragg peak, where the protons come to a halt and deliver their energy. This is particularly advantageous in treating tumors very near critical structures. (See <a href=\"topic.htm?path=radiation-therapy-techniques-in-cancer-treatment#H1070824853\" class=\"medical medical_review\">&quot;Radiation therapy techniques in cancer treatment&quot;, section on 'Particle therapy'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h3\">Radiation dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For fractionated treatment schedules using conformal RT techniques, doses above 54 to 55 Gy significantly improve the likelihood of local tumor control compared with lower doses [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/34-36\" class=\"abstract_t\">34-36</a>]. In a retrospective series, the recurrence rate was significantly higher in patients receiving &le;54 Gy compared with higher doses (50 versus 15 percent) [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Cyst management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Techniques that decrease cyst size are generally indicated when a cyst compresses visual or hypothalamic structures or causes symptomatic obstruction of the third ventricle. Surgical removal of the tumor is the most definitive treatment. Cysts recurrent after surgery may be treated in several ways.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Aspiration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Percutaneous aspiration of cyst contents has been used to alleviate symptoms, and intermittent aspiration may be recommended whenever total excision is not feasible [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/37,38\" class=\"abstract_t\">37,38</a>]. An alternative is placement of an Ommaya reservoir system for intermittent aspiration of a cyst that cannot be completely resected [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/39\" class=\"abstract_t\">39</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Intracavitary irradiation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One approach in patients with solitary or multicystic tumors is intracavitary irradiation via stereotactically applied radioisotopes [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/40-47\" class=\"abstract_t\">40-47</a>]. Beta-emitting isotopes such as yttrium-90 (90Yt), rhenium-186 (186Rh), and phosphorus-32 (32P) are preferred because of the limited penetrance of the emitted energy and the relative ease of handling.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Intracavitary chemotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An alternative approach to intracavitary irradiation uses <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a> [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/48\" class=\"abstract_t\">48</a>]. Experience is more limited than with intracavitary irradiation. In one series of 17 children, intracystic bleomycin was well tolerated, with five complete remissions and a median progression-free interval of 1.8 years [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/49\" class=\"abstract_t\">49</a>]. Intracavitary interferon alfa has also been used at selected centers [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/50-52\" class=\"abstract_t\">50-52</a>]. This approach may have a role in delaying RT or aggressive surgery.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Disease control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Complete surgical resection is the goal of initial treatment, and improvements in surgical techniques have increased the frequency with which a complete resection can be achieved without excessive morbidity or mortality [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/53,54\" class=\"abstract_t\">53,54</a>]. However, the benefits of surgery must be balanced against treatment-related morbidity. (See <a href=\"#H9\" class=\"local\">'Surgery'</a> above.)</p><p>RT is widely used as an adjuvant following subtotal resection, and this approach significantly reduces the risk of a local recurrence [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/55-60\" class=\"abstract_t\">55-60</a>]. The impact of adjuvant RT on overall survival is less clear, probably reflecting the effectiveness of RT as salvage therapy for recurrent disease. There are no randomized trials that compare adjuvant RT with observation followed by salvage RT for recurrent disease.</p><p>The following reports from large series illustrate the range of findings using contemporary surgical and RT techniques:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In 75 patients treated for craniopharyngioma at a single institution over a 27-year period, all patients underwent an attempt at gross total excision [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/55\" class=\"abstract_t\">55</a>]. Postoperative RT was given to 18 of the 27 in whom only a subtotal resection was possible. RT was also given to 22 patients who experienced a local relapse following surgery alone. At a median follow-up of 7.6 years, the 10-year local control rate was significantly better for the patients with a subtotal resection plus RT compared with the 57 patients treated with surgery alone, 48 of whom originally had a complete resection (84 versus 42 percent). The overall survival for the entire cohort was 85 percent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In 121 patients treated between 1963 and 2002, 19 underwent gross total removal, 84 partial resection, and nine cyst evacuation [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/56\" class=\"abstract_t\">56</a>]. All of the patients able to undergo gross total resection were free of recurrence at 10 years. Among those managed with partial resection, the 10-year recurrence-free rates were 77 and 38 percent, with and without postoperative RT.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stereotactic RT (52 Gy in 1.8 Gy fractions) was used to treat 40 patients (28 with recurrent disease, 12 as an adjuvant after surgery) [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/28\" class=\"abstract_t\">28</a>]. At a median follow-up of 98 months, local control was 100 percent at ten years and overall survival was 89 percent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>46 patients with craniopharyngioma underwent 51 courses of treatment with SRS for residual or recurrent craniopharyngioma (median tumor volume 1.0 cm3) [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/30\" class=\"abstract_t\">30</a>]. At a mean follow-up of over five years, the five-year overall and progression-free survival rates were 97 and 92 percent, respectively.</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Treatment complications</span></p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Endocrine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A wide range of endocrine complications are observed in patients with craniopharyngioma following treatment; these likely contribute to the increased mortality of patients with craniopharyngioma [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/61\" class=\"abstract_t\">61</a>]. Endocrine abnormalities are due in part to the original tumor but can be exacerbated by treatment.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Panhypopituitarism is present in the majority of cases and can be manifested by hypogonadism, hypothyroidism, adrenal insufficiency, <span class=\"nowrap\">and/or</span> growth hormone deficiency [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/62\" class=\"abstract_t\">62</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-hypopituitarism\" class=\"medical medical_review\">&quot;Clinical manifestations of hypopituitarism&quot;</a> and <a href=\"topic.htm?path=diagnostic-testing-for-hypopituitarism\" class=\"medical medical_review\">&quot;Diagnostic testing for hypopituitarism&quot;</a> and <a href=\"topic.htm?path=treatment-of-hypopituitarism\" class=\"medical medical_review\">&quot;Treatment of hypopituitarism&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypothalamic dysfunction can cause disabling obesity, disorders of temperature regulation, sleep disorders, or diabetes insipidus. (See <a href=\"topic.htm?path=obesity-in-adults-etiology-and-natural-history#H28\" class=\"medical medical_review\">&quot;Obesity in adults: Etiology and natural history&quot;, section on 'Hypothalamic obesity'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-causes-of-central-diabetes-insipidus\" class=\"medical medical_review\">&quot;Clinical manifestations and causes of central diabetes insipidus&quot;</a> and <a href=\"topic.htm?path=treatment-of-central-diabetes-insipidus\" class=\"medical medical_review\">&quot;Treatment of central diabetes insipidus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complications of obesity, including metabolic syndrome, type 2 diabetes mellitus, and nonalcoholic liver disease [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/63\" class=\"abstract_t\">63</a>]. </p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Neurologic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Common neurologic complications include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neurocognitive deficits, particularly among patients with hypothalamic involvement [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/64,65\" class=\"abstract_t\">64,65</a>] </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypothalamic obesity [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/66,67\" class=\"abstract_t\">66,67</a>] (see <a href=\"topic.htm?path=obesity-in-adults-etiology-and-natural-history#H27\" class=\"medical medical_review\">&quot;Obesity in adults: Etiology and natural history&quot;, section on 'Neuroendocrine obesity'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sleep disorders and a disrupted circadian rhythm [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/68,69\" class=\"abstract_t\">68,69</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Behavioral problems [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/70\" class=\"abstract_t\">70</a>]</p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Visual</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients have visual deficits prior to treatment. These may be exacerbated by either surgery or radiation therapy.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h3\">Vascular abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of vascular abnormalities can follow radiation of a craniopharyngioma in a child. As an example, in one series of 20 patients who underwent imaging following treatment, six had abnormalities, including temporal cavernomas, moyamoya syndrome, aneurysms, and decreases in arterial caliber [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/71\" class=\"abstract_t\">71</a>].</p><p>Patients may also be at increased risk for cerebrovascular disease as a consequence of therapy [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/61,62\" class=\"abstract_t\">61,62</a>]. In a retrospective series of 123 patients with craniopharyngioma treated with multimodality therapy, 14 patients experienced transient ischemic attack or stroke; of these, 2 were in the immediate postoperative period and 12 occurred at a median of 4.4 years after receipt of radiation [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/62\" class=\"abstract_t\">62</a>]. A small cross-sectional cohort study observed a trend suggesting that long-term replacement of growth hormone may reduce the risk of stroke [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/72\" class=\"abstract_t\">72</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h3\">Secondary malignancies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of RT to treat craniopharyngiomas has been associated with the secondary development of meningioma and malignant glial tumors [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/62,73\" class=\"abstract_t\">62,73</a>]. (See <a href=\"topic.htm?path=risk-factors-for-brain-tumors#H8\" class=\"medical medical_review\">&quot;Risk factors for brain tumors&quot;, section on 'Radiation'</a>.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">RECURRENT DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most recurrences are local; surgery, whether used initially or not, may be indicated, as may be radiosurgery, if enlarging focal solid disease rather than cyst expansion is the problem [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/74\" class=\"abstract_t\">74</a>]. In addition, molecularly targeted therapy is likely to play a role in the management of BRAF-mutant tumors in the near future. &#160;</p><p>Malignant transformation is rare but has been reported, usually after multiple recurrences and radiation therapy [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/75,76\" class=\"abstract_t\">75,76</a>]. Remote recurrences can occur, possibly as a consequence of seeding through the cerebrospinal fluid during surgery [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/77-80\" class=\"abstract_t\">77-80</a>]. Treatment of recurrent disease is associated with significantly more morbidity and mortality than the initial therapy [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">POST-TREATMENT FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no evidence-based guidelines for follow-up after initial therapy. Key features of patient management include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neuroimaging with magnetic resonance imaging (MRI), on an annual basis. The duration of imaging follow-up depends upon the extent of initial surgery, the presence or absence of residual tumor, and symptomatology.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monitoring of endocrine function with replacement hormone therapy as needed.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Formal assessment of visual function including visual field testing postoperatively and annually thereafter.</p><p/><p class=\"headingAnchor\" id=\"H985761160\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The long-term prognosis following treatment is influenced both by the ability to control tumor and the development of treatment-related complications. In a series of 121 cases, the 10-year survival rate following presentation was 90 percent when non-tumor related deaths were excluded [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/56\" class=\"abstract_t\">56</a>]. In another large series, 10-year progression-free and overall survival rates were 48 and 80 percent, respectively [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/62\" class=\"abstract_t\">62</a>].</p><p>Despite this, late mortality appears to be increased in patients without tumor progression and may be related to complications of treatment, particularly in survivors of childhood craniopharyngioma. As an example, in a series of 41 patients treated over a 37-year period, there were nine deaths (22 percent) overall [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/81\" class=\"abstract_t\">81</a>]. Three of these occurred more than 20 years after presentation, and one occurred between 10 and 20 years. None of these four was directly related to tumor progression. The reported causes of death in these four cases were uncontrolled diabetes insipidus, pontine infarction, panhypopituitarism, and liver failure.</p><p>These observations were further supported by a population-based study of 307 patients with craniopharyngioma followed for a median of nine years [<a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/61\" class=\"abstract_t\">61</a>]. Individuals with craniopharyngioma had a three- to five-fold increase in expected mortality compared with the general population. The major contributors to excess mortality were cerebrovascular disease (standardized mortality ratio [SMR] 5.1), type 2 diabetes mellitus (SMR 5.6), myocardial infarction (SMR 2.1), and severe infection (SMR 5.9).</p><p>Many series have relatively short follow-up, and longer duration of follow-up is necessary to assess results. However, long-term studies often utilized older surgical and radiation therapy techniques, and patients treated with contemporary techniques may have better outcomes.</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of the patient with a craniopharyngioma involves a balance between controlling the disease and minimizing the side effects of treatment.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Individuals should be managed by a multidisciplinary team with experience in the treatment of craniopharyngioma. The team should include neurosurgery, radiation therapy, neuro-oncology, endocrine, and ophthalmologic expertise. (See <a href=\"#H8\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial management approach is neurosurgical resection, with the goal of removing as much of the tumor as possible, while avoiding severe treatment-induced deficits. (See <a href=\"#H8\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who are not able to undergo a complete resection of their tumor, postoperative radiation therapy rather than observation with salvage RT if a recurrence occurs is recommended (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H8\" class=\"local\">'Treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/1\" class=\"nounderline abstract_t\">Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer 1976; 37:1944.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/2\" class=\"nounderline abstract_t\">Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998; 89:547.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/3\" class=\"nounderline abstract_t\">Jane JA Jr, Laws ER. Craniopharyngioma. Pituitary 2006; 9:323.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/4\" class=\"nounderline abstract_t\">Garr&egrave; ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr 2007; 19:471.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/5\" class=\"nounderline abstract_t\">Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol 1994; 23:458.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/6\" class=\"nounderline abstract_t\">Izuora GI, Ikerionwu S, Saddeqi N, Iloeje SO. Childhood intracranial neoplasms Enugu, Nigeria. West Afr J Med 1989; 8:171.</a></li><li class=\"breakAll\">WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/8\" class=\"nounderline abstract_t\">Laws ER Jr. Transsphenoidal microsurgery in the management of craniopharyngioma. J Neurosurg 1980; 52:661.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/9\" class=\"nounderline abstract_t\">NORTHFIELD DW. Rathke-pouch tumours. Brain 1957; 80:293.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/10\" class=\"nounderline abstract_t\">Rush JA, Younge BR, Campbell RJ, MacCarty CS. Optic glioma. Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 1982; 89:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/11\" class=\"nounderline abstract_t\">Bollati A, Giunta F, Lenzi A, Marini G. Third ventricle intrinsic craniopharingioma. Case report. J Neurosurg Sci 1974; 18:216.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/12\" class=\"nounderline abstract_t\">Cashion EL, Young JM. Intraventricular craniopharyngioma. Report of two cases. J Neurosurg 1971; 34:84.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/13\" class=\"nounderline abstract_t\">Buslei R, Nolde M, Hofmann B, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 2005; 109:589.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/14\" class=\"nounderline abstract_t\">Sekine S, Shibata T, Kokubu A, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 2002; 161:1997.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/15\" class=\"nounderline abstract_t\">Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014; 46:161.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/16\" class=\"nounderline abstract_t\">Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 1994; 35:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/17\" class=\"nounderline abstract_t\">Crotty TB, Scheithauer BW, Young WF Jr, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 1995; 83:206.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/18\" class=\"nounderline abstract_t\">Duff J, Meyer FB, Ilstrup DM, et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000; 46:291.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/19\" class=\"nounderline abstract_t\">Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharyngioma. Orphanet J Rare Dis 2007; 2:18.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/20\" class=\"nounderline abstract_t\">Khan RB, Merchant TE, Boop FA, et al. Headaches in children with craniopharyngioma. J Child Neurol 2013; 28:1622.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/21\" class=\"nounderline abstract_t\">Lober RM, Harsh GR 4th. A perspective on craniopharyngioma. World Neurosurg 2013; 79:645.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/22\" class=\"nounderline abstract_t\">Honegger J, Tatagiba M. Craniopharyngioma surgery. Pituitary 2008; 11:361.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/23\" class=\"nounderline abstract_t\">de Divitiis E, Cappabianca P, Cavallo LM, et al. Extended endoscopic transsphenoidal approach for extrasellar craniopharyngiomas. Neurosurgery 2007; 61:219.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/24\" class=\"nounderline abstract_t\">Cohen M, Bartels U, Branson H, et al. Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011. Neuro Oncol 2013; 15:767.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/25\" class=\"nounderline abstract_t\">Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2013; 98:2376.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/26\" class=\"nounderline abstract_t\">Minniti G, Esposito V, Amichetti M, Enrici RM. The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma. Neurosurg Rev 2009; 32:125.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/27\" class=\"nounderline abstract_t\">Jalali R, Gupta T, Goda JS, et al. Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial. JAMA Oncol 2017; 3:1368.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/28\" class=\"nounderline abstract_t\">Combs SE, Thilmann C, Huber PE, et al. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer 2007; 109:2308.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/29\" class=\"nounderline abstract_t\">Kobayashi T. Long-term results of gamma knife radiosurgery for 100 consecutive cases of craniopharyngioma and a treatment strategy. Prog Neurol Surg 2009; 22:63.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/30\" class=\"nounderline abstract_t\">Niranjan A, Kano H, Mathieu D, et al. Radiosurgery for craniopharyngioma. Int J Radiat Oncol Biol Phys 2010; 78:64.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/31\" class=\"nounderline abstract_t\">Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006; 64:1348.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/32\" class=\"nounderline abstract_t\">Luu QT, Loredo LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J 2006; 12:155.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/33\" class=\"nounderline abstract_t\">Bishop AJ, Greenfield B, Mahajan A, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 2014; 90:354.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/34\" class=\"nounderline abstract_t\">Regine WF, Kramer S. Pediatric craniopharyngiomas: long term results of combined treatment with surgery and radiation. Int J Radiat Oncol Biol Phys 1992; 24:611.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/35\" class=\"nounderline abstract_t\">Habrand JL, Ganry O, Couanet D, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys 1999; 44:255.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/36\" class=\"nounderline abstract_t\">Varlotto JM, Flickinger JC, Kondziolka D, et al. External beam irradiation of craniopharyngiomas: long-term analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 2002; 54:492.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/37\" class=\"nounderline abstract_t\">McMurry FG, Hardy RW Jr, Dohn DF, et al. Long term results in the management of craniopharyngiomas. Neurosurgery 1977; 1:238.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/38\" class=\"nounderline abstract_t\">Ignelzi RJ, Squire LR. Recovery from anterograde and retrograde amnesia after percutaneous drainage of a cystic craniopharyngioma. J Neurol Neurosurg Psychiatry 1976; 39:1231.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/39\" class=\"nounderline abstract_t\">Gutin PH, Klemme WM, Lagger RL, et al. Management of the unresectable cystic craniopharyngioma by aspiration through an Ommaya reservoir drainage system. J Neurosurg 1980; 52:36.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/40\" class=\"nounderline abstract_t\">Manaka S, Teramoto A, Takakura K. The efficacy of radiotherapy for craniopharyngioma. J Neurosurg 1985; 62:648.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/41\" class=\"nounderline abstract_t\">Huk WJ, Mahlstedt J. Intracystic radiotherapy (90Y) of craniopharyngiomas: CT-guided stereotaxic implantation of indwelling drainage system. AJNR Am J Neuroradiol 1983; 4:803.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/42\" class=\"nounderline abstract_t\">Julow J, L&aacute;nyi F, Hajda M, et al. The radiotherapy of cystic craniopharyngioma with intracystic installation of 90Y silicate colloid. Acta Neurochir (Wien) 1985; 74:94.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/43\" class=\"nounderline abstract_t\">Voges J, Sturm V, Lehrke R, et al. Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources. Neurosurgery 1997; 40:263.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/44\" class=\"nounderline abstract_t\">Pollock BE, Lunsford LD, Kondziolka D, et al. Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results. Int J Radiat Oncol Biol Phys 1995; 33:437.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/45\" class=\"nounderline abstract_t\">Backlund EO, Johansson L, Sarby B. Studies on craniopharyngiomas. II. Treatment by stereotaxis and radiosurgery. Acta Chir Scand 1972; 138:749.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/46\" class=\"nounderline abstract_t\">Van den Berge JH, Blaauw G, Breeman WA, et al. Intracavitary brachytherapy of cystic craniopharyngiomas. J Neurosurg 1992; 77:545.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/47\" class=\"nounderline abstract_t\">Barriger RB, Chang A, Lo SS, et al. Phosphorus-32 therapy for cystic craniopharyngiomas. Radiother Oncol 2011; 98:207.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/48\" class=\"nounderline abstract_t\">Zhang S, Fang Y, Cai BW, et al. Intracystic bleomycin for cystic craniopharyngiomas in children. Cochrane Database Syst Rev 2016; 7:CD008890.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/49\" class=\"nounderline abstract_t\">Hukin J, Steinbok P, Lafay-Cousin L, et al. Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience. Cancer 2007; 109:2124.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/50\" class=\"nounderline abstract_t\">Kilday JP, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol 2017; 19:1398.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/51\" class=\"nounderline abstract_t\">Cavalheiro S, Dastoli PA, Silva NS, et al. Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst 2005; 21:719.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/52\" class=\"nounderline abstract_t\">Cavalheiro S, Di Rocco C, Valenzuela S, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus 2010; 28:E12.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/53\" class=\"nounderline abstract_t\">Shi XE, Wu B, Fan T, et al. Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 2008; 110:151.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/54\" class=\"nounderline abstract_t\">Elliott RE, Hsieh K, Hochm T, et al. Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children. J Neurosurg Pediatr 2010; 5:30.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/55\" class=\"nounderline abstract_t\">Stripp DC, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys 2004; 58:714.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/56\" class=\"nounderline abstract_t\">Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62:397.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/57\" class=\"nounderline abstract_t\">Lin LL, El Naqa I, Leonard JR, et al. Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. J Neurosurg Pediatr 2008; 1:126.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/58\" class=\"nounderline abstract_t\">Mark RJ, Lutge WR, Shimizu KT, et al. Craniopharyngioma: treatment in the CT and MR imaging era. Radiology 1995; 197:195.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/59\" class=\"nounderline abstract_t\">Honegger J, Buchfelder M, Fahlbusch R. Surgical treatment of craniopharyngiomas: endocrinological results. J Neurosurg 1999; 90:251.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/60\" class=\"nounderline abstract_t\">Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999; 90:237.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/61\" class=\"nounderline abstract_t\">Olsson DS, Andersson E, Bryngelsson IL, et al. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 2015; 100:467.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/62\" class=\"nounderline abstract_t\">Lo AC, Howard AF, Nichol A, et al. Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int J Radiat Oncol Biol Phys 2014; 88:1011.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/63\" class=\"nounderline abstract_t\">Hoffmann A, Bootsveld K, Gebhardt U, et al. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol 2015; 173:389.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/64\" class=\"nounderline abstract_t\">Fjalldal S, Holmer H, Rylander L, et al. Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma. J Clin Endocrinol Metab 2013; 98:3253.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/65\" class=\"nounderline abstract_t\">&Ouml;zyurt J, M&uuml;ller HL, Thiel CM. A systematic review of cognitive performance in patients with childhood craniopharyngioma. J Neurooncol 2015; 125:9.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/66\" class=\"nounderline abstract_t\">M&uuml;ller HL, Bruhnken G, Emser A, et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst 2005; 21:975.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/67\" class=\"nounderline abstract_t\">Ahmet A, Blaser S, Stephens D, et al. Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab 2006; 19:121.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/68\" class=\"nounderline abstract_t\">Lipton J, Megerian JT, Kothare SV, et al. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology 2009; 73:323.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/69\" class=\"nounderline abstract_t\">van der Klaauw AA, Biermasz NR, Pereira AM, et al. Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. Clin Endocrinol (Oxf) 2008; 69:769.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/70\" class=\"nounderline abstract_t\">Dolson EP, Conklin HM, Li C, et al. Predicting behavioral problems in craniopharyngioma survivors after conformal radiation therapy. Pediatr Blood Cancer 2009; 52:860.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/71\" class=\"nounderline abstract_t\">Liu AK, Bagrosky B, Fenton LZ, et al. Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer 2009; 52:227.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/72\" class=\"nounderline abstract_t\">Lo AC, Howard AF, Nichol A, et al. A Cross-Sectional Cohort Study of Cerebrovascular Disease and Late Effects After Radiation Therapy for Craniopharyngioma. Pediatr Blood Cancer 2016; 63:786.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/73\" class=\"nounderline abstract_t\">Enchev Y, Ferdinandov D, Kounin G, et al. Radiation-induced gliomas following radiotherapy for craniopharyngiomas: a case report and review of the literature. Clin Neurol Neurosurg 2009; 111:591.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/74\" class=\"nounderline abstract_t\">Wisoff JH. Surgical management of recurrent craniopharyngiomas. Pediatr Neurosurg 1994; 21 Suppl 1:108.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/75\" class=\"nounderline abstract_t\">Rodriguez FJ, Scheithauer BW, Tsunoda S, et al. The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol 2007; 31:1020.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/76\" class=\"nounderline abstract_t\">Boongird A, Laothamatas J, Larbcharoensub N, Phudhichareonrat S. Malignant craniopharyngioma; case report and review of the literature. Neuropathology 2009; 29:591.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/77\" class=\"nounderline abstract_t\">Lermen O, Frank S, Hassler W. Postoperative spinal recurrence of craniopharyngioma. Acta Neurochir (Wien) 2010; 152:309.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/78\" class=\"nounderline abstract_t\">Elliott RE, Moshel YA, Wisoff JH. Surgical treatment of ectopic recurrence of craniopharyngioma. Report of 4 cases. J Neurosurg Pediatr 2009; 4:105.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/79\" class=\"nounderline abstract_t\">Frangou EM, Tynan JR, Robinson CA, et al. Metastatic craniopharyngioma: case report and literature review. Childs Nerv Syst 2009; 25:1143.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/80\" class=\"nounderline abstract_t\">Romani R, Niemel&auml; M, Celik O, et al. Ectopic recurrence of craniopharyngioma along the surgical route: case report and literature review. Acta Neurochir (Wien) 2010; 152:297.</a></li><li><a href=\"https://www.uptodate.com/contents/craniopharyngioma/abstract/81\" class=\"nounderline abstract_t\">Visser J, Hukin J, Sargent M, et al. Late mortality in pediatric patients with craniopharyngioma. J Neurooncol 2010; 100:105.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5210 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H26\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOLOGY AND MOLECULAR GENETICS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL PRESENTATION</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSIS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Neuroimaging</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Pretreatment evaluation</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">TREATMENT</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Surgery</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Radiation therapy</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">- RT techniques</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">- Radiation dose</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">Cyst management</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">- Aspiration</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Intracavitary irradiation</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Intracavitary chemotherapy</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">Disease control</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Treatment complications</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">- Endocrine</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Neurologic</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">- Visual</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">- Vascular abnormalities</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">- Secondary malignancies</a></li></ul></li></ul></li><li><a href=\"#H24\" id=\"outline-link-H24\">RECURRENT DISEASE</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">POST-TREATMENT FOLLOW-UP</a></li><li><a href=\"#H985761160\" id=\"outline-link-H985761160\">PROGNOSIS</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/5210|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/70146\" class=\"graphic graphic_diagnosticimage\">- Craniopharyngioma CT</a></li><li><a href=\"image.htm?imageKey=ONC/72783\" class=\"graphic graphic_diagnosticimage\">- Craniopharyngioma MRI I</a></li><li><a href=\"image.htm?imageKey=ONC/80882\" class=\"graphic graphic_diagnosticimage\">- Craniopharyngioma MRI II</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=causes-presentation-and-evaluation-of-sellar-masses\" class=\"medical medical_review\">Causes, presentation, and evaluation of sellar masses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-causes-of-central-diabetes-insipidus\" class=\"medical medical_review\">Clinical manifestations and causes of central diabetes insipidus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-hypopituitarism\" class=\"medical medical_review\">Clinical manifestations of hypopituitarism</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-adrenal-insufficiency-in-adults\" class=\"medical medical_review\">Diagnosis of adrenal insufficiency in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-testing-for-hypopituitarism\" class=\"medical medical_review\">Diagnostic testing for hypopituitarism</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-elevated-intracranial-pressure-in-adults\" class=\"medical medical_review\">Evaluation and management of elevated intracranial pressure in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-vasogenic-edema-in-patients-with-primary-and-metastatic-brain-tumors\" class=\"medical medical_review\">Management of vasogenic edema in patients with primary and metastatic brain tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=obesity-in-adults-etiology-and-natural-history\" class=\"medical medical_review\">Obesity in adults: Etiology and natural history</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-therapy-techniques-in-cancer-treatment\" class=\"medical medical_review\">Radiation therapy techniques in cancer treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-factors-for-brain-tumors\" class=\"medical medical_review\">Risk factors for brain tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stereotactic-cranial-radiosurgery\" class=\"medical medical_review\">Stereotactic cranial radiosurgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-central-diabetes-insipidus\" class=\"medical medical_review\">Treatment of central diabetes insipidus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hypopituitarism\" class=\"medical medical_review\">Treatment of hypopituitarism</a></li></ul></div></div>","javascript":null}